Prostate Cancer Screening

Research output: Contribution to journalReview articlepeer-review

113 Scopus citations


During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with high-risk factors. PCa screening significantly reduces PCa morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)199-214
Number of pages16
JournalMedical Clinics of North America
Issue number2
StatePublished - Mar 2018


  • History of prostate cancer screening
  • PSA
  • Prostate
  • Prostate cancer
  • Prostate cancer screening
  • Prostate cancer screening guidelines
  • Prostate-specific antigen
  • United States Preventive services Task Force

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Prostate Cancer Screening'. Together they form a unique fingerprint.

Cite this